Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Clinical evidence

Neonatal pyruvate dehydrogenase deficiency with lipoate-responsive lactic acidaemia

5 evidence topics · 1 source

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria

No evidence found.

Treatment
Study outcomes
Rationale for using blood lactate as a biochemical outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

The participant received multiple treatment modalities, and the reported lactate response was attributed to lipoic acid rather than isolated dichloroacetate exposure. Death at 1 year 8 months and the absence of a comparator prevent interpreting biochemical improvement as a demonstrated survival benefit.